Enhanced Maternal and Baby Results with AI-supported Care and Empowerment (EMBRACE)

Harnessing digital technologies and AI to support lifelong health for mothers, babies and families
A suite of interrelated projects will collect clinical and multimodal digital data from a global cohort of 60,000 pregnant women, their partners, and babies, using wearable devices, smartphones, and other health monitoring technologies.
This comprehensive dataset will allow the team to develop a holistic and personalised understanding of the factors influencing health during pregnancy and the first 1,000 days of life.
Drawing on these insights, a clinical trial in the UK will test a new blended ‘human-AI health assistant’ that integrates digital platforms with human support. This adaptive assistant will provide tailored interventions throughout pregnancy and early childhood, empowering families to achieve and sustain better long-term health.
This project is made possible thanks to a philanthropic donation of £35m over six years from Inkfish.
Our aim
The EMBRACE project aims to improve health outcomes for mothers and babies worldwide by addressing common risks during and after pregnancy. While many women face lasting health challenges, regular physical activity can help prevent many of these issues. However, most pregnant women do not get enough exercise due to various barriers. EMBRACE will use data-driven approaches to promote better health for families globally.
We are collaborating extensively with international clinical and industry partners, leveraging cutting-edge expertise and innovation.
Join the team
EMBRACE is currently recruiting new research team members. If you’re interested in joining us, we’d love to hear from you - please get in touch!
EMBRACE Scientific Advisors
- Professor Kypros Nicolaides (King's College London)
- Professor Lucilla Poston (King's College London)
- Professor Margie Davenport (University of Alberta)
Principal Investigator
Affiliations
Funding
Amount: This project is supported by a philanthropic donation of £35m from Inkfish.
Period: March 2025 - March 2031